Central serotonin2C receptor: From physiology to pathology

Current Topics in Medicinal Chemistry

Volumn 6, Issue 18, 2006, Pages 1909-1925

  Di Giovanni, Giuseppe ^a   Di Matteo, Vincenzo ^b   Pierucci, Massimo ^b   Benigno, Arcangelo ^a   Esposito, Ennio ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Depression; Drug of abuse; Schizophrenia; Selective 5 HT2c drugs; Serotonergic receptors

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; OPIPRAMOL; PHENCYCLIDINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SPIPERONE; TRAZODONE; UNINDEXED DRUG;

AMINO ACID SEQUENCE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; EATING DISORDER; EPILEPSY; GENE MUTATION; HUMAN; LIGAND BINDING; MAJOR DEPRESSION; MULTIPLE DRUG DOSE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN STRUCTURE; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SEQUENCE HOMOLOGY; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM; PROTEIN CONFORMATION;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; PROTEIN CONFORMATION; RECEPTOR, SEROTONIN, 5-HT2C; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 33749519179     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606778522113     Document Type: Review

References (225)

1. Twarog, B. M.; Page, I. H. Serotonin content of some mammalian tissues and mine and a modelfor its determination. Am. J. Physiol. 1953, 175, 157-161.
2. Brodie, B. B.; Pletscher, A.; Shore, P. A. Evidence that serotonin has a role in brain flinctions. Science 1955, 122, 968.
3. Whitaker-Azmitia, P. M. The discovery of serotonin and its role in neuroscience. Neuropsychopharmacology 1999, 21, 2S-8S.
4. Dahlström, A.; Fuxe, K. Evidence for the existence of monamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. 1964, 62, 1-55.
5. Moukhles, H.; Bosler, O.; Bolam, J. P.; Vallee, A.; Umbriaco, D.; Geffard, M.; Doucet G. Quantitative and morphometric data indicate precise cellular interactions between serotonin terminals and postsynaptic targets in rat substantia nigra. Neuroscience 1997, 76, 1159-1171.
6. Van Bockstaele, E J.; Biswas, A.; Pickel, V. M. Topography of serotonin neurons in the dorsal raphe nucleus that send axon collaterals to the rat prefrontal cortex and nucleus accumbens. Brain Res. 1993, 624, 188-198.
7. Van Bockstaele, E. J.; Cestari, D. M.; Pickel, V. M. Synaptic structure and connectivity of serotonin terminals in the ventral tegmental area: potential sites for modulation of mesolimbic dopamine neurons. Brain Res. 1994, 647, 307-322.
8. Herve, D.; Pickel, V. M.; Joh, T. H.; Beaudet, A. Serotonin axon terminals in the ventral tegmental area of the rat: finestructure and synaptic input to dopaminergic neurons. Brain Res. 1987, 435, 71-83.
9. Kalivas, P. W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Brain Res. Rev. 1993, 18, 75-113.
10. Azmitia, E. C.; Segal, M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol. 1978, 179, 641-667.
11. McQuade, R.; Sharp, T. Release of cerebral 5-hydroxytryptamine evoked by electrical stimulation of the dorsal and median raphe nuclei: effect of a neurotoxic amphetamine. Neuroscience 1995, 68, 1079-1088.
12. McQuade, R.; Sharp, T. Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J. Neurochem. 1997, 69, 791-796.
13. Jacobs, B. L.; Azmitia, E. C. Structure and function of the brain serotonin system. Physiol. Rev. 1992, 72, 165-229.
14. Gaddum, J. H.; Picarelli, Z. P. Two kinds of tryptamine receptors. Br. J. Pharmacol. 1957, 12, 323-328.
15. Peroutka, S. J.: Snyder, S. H. Multiple serotonin receptors: differential binding of [3H)5-hydroxytryptamine, [3H] lysergic acid diethylamide and [3H]spiroperidol. Mol. Pharmacol. 1979, 16, 687-699.
16. Hoyer, D.; Hannon, J. P.; Martin, G. R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 2002, 71, 533-54.
17. Barnes, N. M.; Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38, 1083-1152.
18. Leonard, D. A.; Evans, T.; Hart, M.; Cerione, R. A.; Manor, D. Investigation of the GTP-binding/GTPase cycle of Cdc42Hs using fluorescencespectroscopy. Biochemistry 1994, 33, 12323-12328.
19. Kroeze, W. K.; Kristiansen, K.; Roth, B. L. Molecular biology of serotonin receptors structure and function at the molecular level. Curr. Top. Med. Chem. 2002, 2, 507-528.
20. Zifa, E.; Fillion, G. 5-Hydroxytryptamine receptors. Pharmacol. Rev. 1992, 44, 401-458.
21. Boess, F. G.; Martin, I. L. Molecular biology of 5-HT receptors. Neuropharmacology 1994, 33, 275-317.
22. Hapfelmeier, G.; Tredt, C.; Haseneder, R.; Zieglgansberger, W.; Eisensamer, B.; Rupprecht, R.; Rammes, G. Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 receptor. Biophys. J. 2003, 84, 1720-1733.
23. Niesler, B.; Frank, B.; Kapeller, J.; Rappold, G. A. Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes -HTR3C, -HTR3D and -HTR3E. Gene 2003, 310, 101-111.
24. Roth, B. L.; Craigo, S. C.; Choudhary, M. S.; Uluer, A.; Monsma, F. J. Jr.; Shen, Y.; Meltzer, H. Y.; Sibley, D. R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 1994, 268, 1403-1410.
25. Erlander, M. G.; Lovenberg, T. W.; Baron, B. M.; de Lecea L, Danielson, P. E.; Racke, M.; Slone, A. L.; Siegel, B. W.; Foye, P. E.; Cannon, K.; Burns, J. E.; Sutcliff, J. G. Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. Proc. Natl. Acad. Sci. USA 1993, 90, 3452-3456.
26. Matthes, H.; Boschert, U.; Amlaiky, N., Grailhe, R.; Plassat, J. L.; Muscatelli, F.; Mattei, M. G.; Hen, R. Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol. Pharmacol. 1993, 43, 313-9.
27. Frank, M. G.; Stryker, M. P.; Tecott, L. H. Sleep and sleep homeostasis in mice lacking the 5-HT2c receptor. Neuropsychopharmacolozy 2002, 27, 869-873.
28. Grailhe, R.; Waeber, C.; Dulawa, S. C.; Hornung, J. P., Zhuang, X; Brunner, D.; Geyer, M. A.; Hen, R. Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. Neuron 1999, 22, 581-91.
29. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Harting, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. A. VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 1994, 46, 157-203.
30. Higgins, G. A.; Fletcher, P. J. Serotonin and drug reward: focus on 5-HT2C receptors. Eur. J. Pharmacol. 2003, 480, 151-162.
31. Isaac, M. Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs. Curr. Top. Med. Chem. 2005, 5, 59-67.
32. Reynolds, G. P.; Templeman, L. A.; Zhang, Z. J. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol. Biol. Psychiatry 2005, 29, 1021-1028.
33. Baxter, G. S.; Kennett, G. A.; Blaney, F.; Blackburn, T. 5-HT2 receptor subtypes: a family reunited? Trends Pharmacol. Sci. 1995, 16, 105-110.
34. Meltzer, H. Y.; Matsubara, S.; Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 1989, 251, 238-246.
35. Roth, B. L.; Meltzer, H. Y.; Khan, N. Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. Adv. Pharmacol. 1998, 42, 482-485.
36. Aghajanian, G. K.; Marek, G. J. Serotonin model of schizophrenia: emergine role of glutamate mechanisms. Brain Res. Brain Res. Rev. 2000, 31, 302-312.
37. Van Oekelen, D.; Luyten, W. H.; Leysen, J. E. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci. 2003, 72, 2429-2449.
38. Li, Q. H.; Nakadate, K.; Tanaka-Nakadate, S.; Nakatsuka, D.; Cui, Y.; Watanabe, Y. Unique expression patterns of 5-HT2A and 5-HT2C receptors in the rat brain during postnatal development: Western blot and immunohistochemical analyses. J. Comp. Neurol. 2004, 469, 128-140.
39. Kcjic. L.; Dyck, R.; H.; Gu, Q.; Douglas, R. M.; Matsubara, J.; Cynader, M. S. Columnar distribution of serotonin-dependent plasticity within kitten striate cortex. Proc. Natl. Acad. Sci. USA 2000, 97, 1841-1844.
40. Berg, K. A.; Clarke, W. P.; Sailstad, C.; Saltzman, A.; Maayani, S. Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. Mol. Pharmacol. 1994, 46, 477-484.
41. Berg, K. A.; Maayani, S.; Goldfarb, J.; Scaramellini, C.; Leff, P.; Clarke, W. P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol. 1998, 54, 94-104.
42. Leysen, J. E. 5-HT2 receptors. Curr. Drug Targets CNS Neurol. Disord. 2004, 3, 11-26.
43. Morilak, D. A.; Somogyi, P.; Lujan-Miras, R.; Ciaranello, R. D. Neurons expressing 5-HT2 receptors in the rat brain: neurochemical identification of cell types by immunocytochemistry. Neuropsychopharmacology 1994, 11, 157-66.
44. Willins, D. L.; Deutch, A. Y.; Roth, B. L. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 1997, 27, 79-82.
45. Jakab, R. L.; Goldman-Rakic, P. S. Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J. Comp. Neurol. 2000, 417, 337-348.
46. Jakab, R. L.; Goldman-Rakic, P. S. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. USA 1998, 95, 735-740.
47. Miner, L. A.; Backstrom, J. R.; Sanders-Bush, E.; Sesack, S. R. Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 2003, 116, 107-117.
48. Cornea-Hebert, V.; Riad, M.; Wu, C.; Singh, S. K.; Descarries, L. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J. Comp. Neurol. 1999, 409, 187-209.
49. Dean, B. The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J. Neurochem. 2003, 85, 1-13.
50. Ikemoto, K.; Nishimura, A.; Okado, N.; Mikuni, M.; Nishi, K.; Nagatsu, I. Human midbrain dopamine neurons express serotonin 2A receptor: an immunohistochemical demonstration. Brain Res. 2000, 853, 377-380.
51. Nocjar, C.; Roth, B. L.; Pehek, E. A. Localization of 5-HT2A receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience 2002, 111, 163-176.
52. Doherty, M. D.; Pickel, V. Ultrastructural localization of serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res. 2000, 864, 176-185.
53. Heider, M.; Schliebs, R.; Rossner, S.; Bigl, V. Basal forebrain cholinergic immunolesion by 192IgG-saporin: evidence for apresynaptic location of subpopulations of alpha 2- and beta-adrenergic as well as 5-HT2A receptors on cortical cholinergic terminals. Neurochem. Res. 1997, 22, 957-966.
54. Fay, R.; Kubin, L. 5-HT(2A) receptor-like protein is present in small neurons located in rat mesopontine cholinergic nuclei, but absent from cholinergic neurons. Neurosci. Lett. 2001, 314, 77-81.
55. Luttgen, M.; Ogren, S. O.; Meister, B. 5-HT1A receptor mRNA and immunoreactivity in the rat medial septum/diagonal band of Broca-relationships to GABAergic and cholinergic neurons. J. Chem. Neuroanat. 2005, 29, 93-111.
56. Enguix, M. J.; Sanchez, L.; Villazon, M.; Brea, J.; Tristan, H.; Caruncho, H. J.; Cadavid, M. I.; Loza, M. I. Differential regulation of rat peripheral 5-HT(2A) and 5-HT(2B) receptor systems: influence of drug treatment. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 368, 79-90.
57. Eglen. R. M. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br. J. Pharmacol. 1995, 115, 622-628.
58. Borman, R. A.; Tilford, N. S.; Harmer, D. W.; Day, N.; Ellis, E. S.; Sheldrick, R. L.; Carey, J.; Coleman, R. A.; Baxter, G. S. 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br. J. Pharmacol. 2002, 135, 1144-51.
59. Loric, S.; Launay, J. M.; Colas, J. F.; Maroteaux, L. New mouse 5-HT2-like receptor. Expression in brain, heart and intestine. FEBS Lett. 1992, 312, 203-207.
60. Foguet, M.; Nguyen, H.; Le, H.; Lubbert, H. Structure of the mouse 5-HT1C, 5-HT2 and stomach fundus serotonin receptor genes. Neuroreport 1992, 3, 345-348.
61. Schmuck, K.; Ullmer, C.; Engels, P.; Lubbert, H. Cloning and functional characterization of the human 5-HT2B serotonin receptor. FEBS Lett. 1994, 342, 85-90.
62. Duxon, M.S.; Flanigan, T. P.; Reavley, A. C.; Baxter, G. S.; Blackburn, T. P.; Fone, K. C. F. Evidence for expression of the 5-hydroxytryptamine2B receptor protein in the rat central nervous system. Neuroscience 1997, 76, 323-329.
63. Nebigil, C. G.; Etienne, N.; Schaerlinger, B.; Hickel, P.; Launay, J. M.; Maroteaux, L. Developmentally regulated serotonin 5-HT2B receptors. Int. J. Dev. Neurosci. 2001, 19, 365-372.
64. Choi, D. S.; Ward, S. J.; Messaddeq, N.; Launay, J. M.; Maroteaux, L. 5-HT2B receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardiac cells. Development 1997, 124, 1745-1755.
65. Di Giovanni, G.; Di Matteo, V.; Esposito, E. Serotonin/dopamine interaction-focus on 5-HT2C receptor, a now target of psychotropic drugs. Indian J. Exp. Biol. 2002, 40, 1344-1352.
66. Kennett, G. A. 5-HT1C receptors and their therapeutic relevance. Curr. Opin. Invest. Drugs 1993, 2, 317-362.
67. Jenck, F.; Bös, J.; Wichmann, J.; Stadler, H.; Martin, J. R.; Moreau, J. L. The role of 5-HT2C receptors in affective disorders. Exp. Opin. Invest. Drugs 1998, 7, 1587-1599.
68. Tecott, L. H.; Sun, L. M.; Akana, S. F.; Strack, A. M.; Lowenstein, D. H.; Dallman, M. F.; Julius, D. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995, 374, 542-546.
69. Heisler, L. K.; Chu, H. M.; Tecott, L. H. Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Ann. N. Y. Acad. Sci. 1998, 861, 74-78.
70. Bickerdike, M. J.; Vickers, S. P.; Dourish, C. T. 5-HT2C receptor modulation and the treatment of obesity. Diabetes Obes. Metab. 1999, 1, 207-214.
71. Bickerdike, M. J. 5-HT2C receptor agonists as potential drugs for the treatment of obesity. Curr. Top. Med. Chem. 2003, 3, 885-897.
72. Applegate, C. D.; Tecott, L. H. Global increases in seizure susceptibility in mice lacking 5-HT2C receptors: a behavioral analysis. Exp. Neurol. 1998, 154, 522-530.
73. Raap, D. K.; Van De Kar, L. D. Selective serotonin-reuptake inhibitors and neuroendocrine function. Life Sci. 1999, 65, 1217-1235.
74. Milatovich, A.; Hsieh, C. L.; Bonaminio, G.; Tecott, L.; Julius, D.; Francke, U. Serotonin receptor 1c gene assigned to X chromosome in human (band q24) and mouse (bands D-F4). Hum. Mol. Genet. 1992, 1, 681-684.
75. Xie, E.; Zhu, L.; Zhao, L.; Chang, L. S. The human serotonin 5-HT2C receptor: complete cDNA, genornic structure, and alternatively spliced variant. Genomics 1996, 35, 551-561.
76. Abramowski, D.; Staufeubiel, M. Identification of the 5-hydroxytryptamine2C receptor as a 60-kDa N-glycosylated protein in choroid plexus and hippocampus. J. Neurochem. 1995, 65, 782-790.
77. Visiers, I.; Hassan, S. A.; Weinstein, H. Differences in conformational properties of the second intracellular loop (IL2) in 5-HT(2C) receptors modified by RNA editing can account for G protein coupling efficiency. Protein Eng. 2001, 14, 409-414.
78. Cypess, A. M.; Unson, C. G.; Wu, C. R.; Sakmar, T. P. Two cytoplasmic loops of the glucagon receptor are required to elevate cAMP or intracellular calcium. J. Biol Chem. 1999, 274, 19455-19464.
79. Sanders-Bush, E.; Fentress, H.; Hazelwood, L. Serotonin 5-ht2 receptors: molecular and genomic diversity. Mol. Interv. 2003, 3, 319-330.
80. Burns. C. M.: Chu. H.: Rueter. S. M.: Hutchinson. L. K.: Canton. H.; Sanders-Bush, E.; Emeson, R. B. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 1997, 387, 303-308.
81. Wang, Q.; O'Brien, P. J.; Chen, C. X.; Cho, D. S.; Murray, J. M.; Nishikura, K. Altered G protein-coupling functions of RNA editing isoform and splicing variant serotonin2C receptors. J. Neurochem. 2000, 74, 1290-1300.
82. Fitzgerald, L. W.; Iyer, G.; Conklin, D. S.; Krause, C. M,; Marshall, A.; Patterson, J. P.; Tran, D. P.; Jonak, G. J.; Hartig, P. R. Messenger RNA editing of the human serotonin 5-HT2C receptor. Neuropsychopharmacology 1999, 21, 82S-90S.
83. Gurevich, I.; Englander, M. T.; Adlersberg, M.; Siegal, N. B.; Schmauss, C. Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission. J. Neurosci. 2002, 22, 10529-10532.
84. Schmauss, C. Serotonin 2C receptors: suicide, serotonin, and runaway RNA editing. Neuroscientist 2003, 9, 237-242.
85. Quirk, K.; Lawrence, A.; Jones, J, Misra, A.; Harvey, V.; Lamb, H.; Revell, D.; Porter, R. H.; Knight, A. R. Characterisation of agonist binding on human 5-HT2C receptor isoforms. Eur. J. Pharmacol. 2001, 419, 107-112.
86. Herrick-Davis, K.; Grinde, E.; Mazurkiewicz, J.E. Biochemical and biophysical characterization of serotonin 5-HT2C receptor homodimers on the plasma membrane of living cells. Biochemistry 2004, 43, 13963-13971.
87. Herrick-Davis, K.; Grinde, E.; Harrigan, T. J.; Mazurkiewicz, J. E. Inhibition of serotonin 5-HT2C receptor function through heterodimerization: Receptor dimers bind two molecules of ligand and one G-protein. J. Biol. Chem. 2005, 280, 40144-40151.
88. Terrillon, S.; Bouvier, M. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 2004, 5, 30-34.
89. de Chaffoy de Courcelles, D.; Leysen, J. E.; De Clerck, F.; Van Belle, H.; Janssen, P. A. Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sites. J. Biol. Chem. 1985, 260, 7603-7608.
90. de Chaffoy de Courcelles, D.; Roevens, P.; Wynants, J.; Van Belle, H. Serotonin-induced alterations in inositol phospholipid metabolism in human platelets. Biochim. Biophys Acta 1987, 927, 291-302.
91. Conn, P. J.; Sanders-Bush, E. Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. J. Neurosci. 1986, 6, 3669-3675.
92. Chang, M.; Zhang, L.; Tam, J.-P.; Sanders-Bush, E. Dissecting G protein-coupled receptor signaling pathways with membrane-permeable blocking peptides. Endogenous 5-HT(2C) receptors in choroid plexus epithelial cells. J. Biol. Chem. 2000, 275, 7021-7029.
93. McGrew, L.; Chang, M. S.; Sanders-Bush, E. Phospholipase D activation by endogenous 5-hydroxytryptamine 2C receptors is mediated by Galpha13 and pertussis toxin-insensitive Gbetagamma subunits. Mol. Pharmacol. 2002, 62, 1339-1343.
94. Werry, T. D.; Gregory, K. J.; Sexton, P. M.; Christopoulos, A. Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. J. Neurochem. 2005, 93, 1603-1615.
95. Cussac, D.; Newman-Tancredi, A.; Duqueyroix, D.; Pasteau, V.; Millan, M. J. Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol. Pharmacol. 2002, 62, 578-589.
96. Berg, K. A.; Cropper, J. D.; Niswender, C. M.; Sanders-Bush, E.; Emeson, R. B.; Clarke, W. P. RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. Br. J. Pharmacol. 2001, 134, 386-392.
97. Barker, E. L., Westphal, R. S.; Schmidt, D.; Sanders-Bush, E. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J. Biol. Chem. 1994, 269, 11687-11690.
98. Berg, K. A.; Stout, B. D.; Cropper, J. D.; Maayani, S.; Clarke, W. P. Novel actions of inverse agonists on 5-HT2C receptor systems. Mol. Pharmacol. 1999, 55, 863-872.
99. Niswender, C. M.; Copeland, S. C.; Herrick-Davis, K.; Emeson, R. B., Sanders-Bush, E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J. Biol. Chem. 1999. 274. 9472-9478.
100. Grotewiel, M. S.; Sanders-Bush, E. Differences in agonist-independent activity of 5-Ht2A and 5-HT2c receptors revealed by heterologous expression. Naunyn. Schmiedebergs Arch. Pharmacol. 1999, 359, 21-27.
101. De Deurwaerdere, P.; Navailles, S.; Berg, K. A.; Clarke, W. P.: Spampinato, U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci. 2004, 24, 3235-3241.
102. Navailles, S.; Deurwaerdere, P. D.; Spampinato, U. Clozapine and Haloperidol Differentially Alter the Constitutive Activity of Central Serotonin(2C) Receptors In Vivo. Biol. Psychiatry. 2006, 59, 568-575.
103. Milligan, G.; Bond, R. A.; Lee, M. Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci. 1995, 16, 10-13.
104. Rauser, L.; Savage, J. E.; Meltzer, H. Y.; Roth, B.,L. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine2C receptor. J. Pharmacol. Exp. Ther. 2001, 299, 83-89.
105. Dwivedi, Y.; Pandey, G. N. Effects of treatment with haloperidol, chlorpromazine, and clozapine on protein kinase C (PKC) and phosphoinositide-specific phospholipase C (PI-PLC) activity and on mRNA and protein expression of PKC and PLC isozymes in rat brain. J. Pharmacol. Exp. Ther. 1999, 291, 688-704.
106. Im, W. B.; Chio, C. L.; Alberts, G. L.; Dinh, D. M. Positive allosteric modulator of the human 5-HT2C receptor. Mol. Pharmacol. 2003, 64, 78-84.
107. Hietala, J.; Koulu, M.; Kuoppamaki, M.; Lappalainen, J.; Syvalahti, E. Chronic clozapine treatment down-regulates serotonin 5-HT-1c receptors in rat brain. Prog. Neuropsychopharmcol. Biol. Psychiatry. 1992, 16, 727-732.
108. Briddon, S. J.; Leslie, R. A.; Elliot, J. M. Comparative desensitization of the human 5-HT2A and 5-HT2C receptors expressed in the human neuroblastoma cell line SH-SY5Y. Br. J. Pharmacol. 1998, 125, 727-734.
109. Pazos, A.; Hoyer, D.; Palacios, J. M. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur. J. Pharmacol. 1984, 106, 539-546.
110. Pazos, A.; Cortes, R.; Palacios, J. M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res. 1985, 346, 231-249.
111. Pazos, A.; Probst, A.; Palacios, J. M. Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987. 21. 123-139.
112. Marazziti, D.; Rossi, A.; Giannaccini, G.; Zavaglia, K. M.; Dell'Osso, L.; Lucacchini, A.; Cassano, G. B. Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Eur. Neuropsychopharmacol. 1999, 10, 21-26.
113. Molineaux, S. M.; Jessell, T. M.; Axel, R.; Julius, D. 5-HT1C receptor is a prominent serotonin receptor subtype in the central nervous system. Proc. Natl., Acad. Sci. USA 1989, 86, 6793-6797.
114. Mengod, G.; Pompeiano, M.; Martinez-Mir, M. I.; Palacios, J. M. Localization of the mRNA for the 5-HT2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res. 1990, 524, 139-143.
115. Pasqualetti, M.; Ori, M.; Castagna, M.; Marazziti, D.; Cassano, G. B.; Nardi, I. Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 1999, 92, 601-611.
116. Lopez-Gimenez, J. F.; Mengod, G.; Palacios, J. M.; Vilaro, M. T. Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA. Synapse 2001, 42, 12-26.
117. Pompeiano, M.; Palacios, J. M.; Mengod, G. Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Mol. Brain Res. 1994, 23, 163-178.
118. Esterle, T. M.: Sanders-Bush, E. Serotonin agonists increase transferrin levels via activation of 5-HT1C receptors in choroid plexus epithelium. J. Neurosci. 1992, 12, 4775-4782.
119. Sharma, A.; Punhani, T.;Fone, K.C. F. Distribution of the 5-hydroxytryptamine2C receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody: effect of 5,7,-dihydroxytryptamine. Synapse 1997, 27, 45-56.
120. Ward, R. P.; Dorsa, D. M. Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C and 5-HT6 with neuropeptides in rat striatum. J. Comp. Neurol. 1996, 370, 405-414.
121. Eberle-Wang, K.; Mikeladze, Z.; Uryu, K.; Chesselet, M-F. Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J. Comp. Neurol. 1997, 384, 233-247.
122. Van Bockstaele, E. J.; Pickel, V. M. GABA-containing neurons in the ventral tegmental area project to the nucleus accumbens in rat brain. Brain Res. 1995, 682, 215-221.
123. Steffensen, S. C.; Svingos, A. L.; Pickel, V. M.; Henriksen, S. J. Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. J. Neurosci. 1998, 18, 8003-8015.
124. Di Giovanni, G.; Di Matteo, V.; La Grutta, V.; Esposito, E. m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors. Neuroscience 2001, 103, 111-116.
125. Hoffman, B. J.; Mezey, E. Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain. FEBS Lett. 1989, 247, 453-62.
126. Wright, D. E.; Seroogy, K. B.; Lundgren, K. H.; Davis, B. M.; Jennes, L. Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J. Comp. Neurol. 1995, 351, 357-373.
127. Serrats, J.; Mengod, G.; Cortes, R. Expression of serotonin 5-HT2C receptors in GABAergic cells of the anterior raphe nuclei. J. Chem. Neuroanat. 2005, 29, 83-91.
128. Liu, R.; Jolas, T.; Aghajanian, G. Serotonin 5-HT(2) receptors/activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res. 2000, 873, 34-45.
129. Fonseca, M. I.; Ni, Y. G.; Dunning, D. D.; Miledi, R. Distribution of serotonin 2A, 2C and 3 receptor mRNA in spinal cord and medulla oblongata. Brain Res. Mol. Brain Res. 2001, 89, 11-19.
130. Kennett, G. A.; Wood, M. D.; Bright, F.; Trail, B.; Riley, G.; Holland, V.; Avenel, K. J.; Stean, T.; Upton, N.; Bromidge, S.; Forbes, I. T.; Brown, A. M.; Middlemiss, D. N.; Blackburn, T. P. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997, 36, 609-620.
131. Abramowski, D.; Rigo, M.; Due, D.; Hoyer, D.; Staufenbiel, M. Localization of 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 1995, 35, 1635-1645.
132. De Deurwaerdère, P.; Spampinato, U. Role of serotonin2A and serotonin2B/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem. 1999, 73, 1033-1042.
133. Gobert, A.; Millan. M. J. Scrotonin 5-HT2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 1999, 38, 315-317.
134. Gobert, A.; Rivet, J-M.; Lejeune, F.; Newman-Tancredi, A.; Adhumeau-Auclair, A.; Nicolas, J-P.; Cistarelli, L.; Melon, C.; Millan, M. J. Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse 2000, 36, 205-221.
135. Lucas, G.; De Deurwaerdère, P.; Caccia, S.; Spampinato, U. The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: Opposite role of 5-HT2A and 5-HT2C receptor subtypes and signif-icance of the haloperidol dose used. Neuropharmacology 2000, 39, 1053-1063.
136. Di Giovanni, G.; De Deurwaerdère, P.; Di Mascio, M.; Di Matteo, V.; Esposito, E.; Spampinato, U. Selective blockade of serotonin2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 1999, 91, 587-597.
137. Di Matteo, V.; Di Giovanni, G.; Di Mascio, M.; Esposito, E. Selective blockade of serotonin 2C/2B receptors enhances dopaminereleasein the rat nucleus accumbens. Neuropharmacology 1998, 37, 265-272.
138. Di Matteo, V.; Di Giovanni, G.; Di Mascio, M.; Esposito, E. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin2C receptors. Brain Res. 2000, 865, 85-90.
139. Di Giovanni, G.; Di Matteo, V.; Di Mascio, M.; Esposito, E. Preferential mod-ulation of mesolimbic versus nigrostriatal dopaminergic function by serotonin2C/2B receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 2000, 35, 53-61.
140. Alex, K. D.; Yavanian, G. J.; McFarlane, H. G.; Pluto, C. P.; Pehek, E. A. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 2005, 55, 242-251.
141. Hutson, P. H.; Barton, C. L.; Jay, M.; Blurton, P.; Burkamp, F.; Clarkson, R.; Bristow, L. J. Activation of mesolimbic dopamine function by phencyclidine is enhanced by 5-HT2C/2B receptor antagonists: Neurochemical and behavioural studies. Neuropharmacology 2000, 39, 2318-2328.
142. Pozzi, L.; Acconcia, S.; Ceglia, I.; Invernizzi R. W.; Samanin, R. Stimulation of 5-hydroxytryptamine (5-HT2C) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J. Neurochem. 2002, 82, 93-100.
143. Willins, D. L.; Meltzer, H. Y. Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens. Brain Res. 1998, 781, 291-299.
144. Prisco, S.; Pagannone, S.; Esposito, E. Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. J. Pharmacol. Exp. Ther. 1994, 271, 83-90.
145. Kennett, G. A.; Wood, M. D.; Bright, F.; Cilia, J.; Piper, D. C.; Gager, T.; Thomas, D. R.; Baxter, G. S.; Forbes, I. T.; Ham, P.; Blackburn, T. P. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br. J. Pharmacol. 1996, 117, 427-434.
146. Di Matteo, V.; Di Giovanni, G.; Di Mascio, M.; Esposito, E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 1999, 38, 1195-1205.
147. Millan, M. J.; Dekene, A.; Gobert, A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT release in the frontal cortex in vivo. Neuropharmacology 1998, 37, 953-955.
148. Giorgetti, M.; Tecott, L. H. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur. J. Pharmacol. 2004, 488, 1-9.
149. Carr, D. B.; Sesack, S. R. GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex. Synapse 2000, 38, 114-123.
150. Anttila, S. A.; Leinonen., E. V.; A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001, 7, 249-264.
151. Millan, M. J.; Gobert, A.; Rivet, J. M.; Adhumeau-Auclair, A.; Cussac, D.; Newman-Tancredi, A.; Dekeyne, A.; Nicolas, J. P.; Lejeune. F. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of (α2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur. J. Neurosci. 2000, 12, 1079-1095.
152. Jenck, F.; Moreau, J. L.; Mutel, V.; Martin, J. R.; Haefely, W. E. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur. J. Pharmacol. 1993, 231, 223-229.
153. Jack, F.; Moreau, J. L.; Mittel, V.; Martin, J. R. Brain 5-HT1C receptors and antidepressants. Progr. Neuropsychopharmacol. Biol. Psychiatr. 1994, 18, 563-574.
154. Ni, Y. G.; Miledi, R. Blockage of 5-HT2C serotonin receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. USA 1997, 94, 2036-2040.
155. Di Matteo, V.; Di Mascio, M.; Di Giovanni, G.; Esposito, E. Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin2C receptors. Psychopharmacology 2000, 150, 45-51.
156. Moreau, J-L.; Jenck, F.; Martin, J. R.; Perrin, S.; Haefely, W. E. Effect of repeated mild stress and two antidepressant treatments on the behavioral response to 5-HT1C receptor activation in rats. Psychopharmacology 1993, 110, 140-144.
157. Moreau, J-L.; Bös, M.; Jenck, F.; Martin, J. R.; Mortas, P.; Wichmann, J. 5-HT2C receptor agonists exhibit antidepressant - like properties in the anhedonia model of depression in rats. Eur. Neuropsychopharmacol. 1996, 6, 169-175.
158. Barker, E. L.; Sanders-Bush, E. 5-Hydroxytryptamine1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl) -2-aminoprovane. Mol. Pharmacol. 1993, 44, 725-730.
159. Pranzatelli, M. R.; Murthy, J. N.; Tailor, P. T. Novel regulation of 5-HT1C receptors: down-reguMon induced both by 5-HT1C/2 receptor agonists and antagonists. Eur. J. Pharmacol. 1993, 244, 1-5.
160. Newton, R. A.; Elliott, J. M. Mianserin-induced down-regulation of human 5-hydroxytryptamine2A and 5-Hydroxytryptamine2C receptors stably expressed in the human neuroblastoma cell line SH-SY5Y. J Neurochem. 1997, 69, 1031-1038.
161. Cryan, J. F.; Lucki, I. Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine2C receptors. J. Pharmacol. Exp. Ther. 2000, 295, 1120-1126.
162. Clenet, F.; De Vos, A.; Bourin, M. Involvement of 5-HT2C receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice. Eur. Neuropsychopharmacology 2001, 11, 145-152.
163. Yamada, J.; Sugimoto, Y. Effects of 5-HT2 receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test in mice Eur. J. Pharmacol. 2001, 427, 221-225.
164. Lerer, B.; Macciardi, F.; Segman, R. H.; Adolfsson, R.; Blackwood, D.; Blairy, S.; Del Favero, J.; Dikeos, D. G.; Kaneva, R.; Lilli, R.; Massat, I.; Milanova, V.; Muir, W.; Noethen, M.; Oruc, L.; Petrova, T.; Papadimitriou, G. N.; Rietschel, M.; Serretti, A.; Souery, D.; Van Gestel, S.; Van Broeckhoven, C.; Mendlewicz, J. Variability of 5-HT2C receptor cys23ser polymorphism among european populations and vulnerability to affective disorder. Mol. Psychiatry 2001, 6, 579-585.
165. 2C receptor potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology 2004, 29, 1782-1789.
166. Gao, K.; Calabrese, J. R. Newer treatment studies for bipolar depression. Bipolar Disord. 2005, 7, 13-23.
167. Prisco, S.; Esposito, E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br. J. Pharmac. 1995, 116, 1923-1931.
168. Maj, J.; Moryl, E. Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J. Neural. Transm. Gen Sec. 1992, 88, 143-156.
169. Kennedy, A. J; Gibson, E. L.; O'Connel, M. T.; Curzon G. Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responce to mCPP. Psychopharmcology 1993; 113, 262-268.
170. Kennett, G A.; Lightowler, S.; de Biasi, V.; Stevens, N. C.; Wood, M. D.; Tulloch, I. F.; Blackburn, T. P. Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 1994, 33, 1581-1588.
171. Yamauchi, M.; Tatebayashi, T.; Nagase, K.; Kojima, M.; Imanishi, T. Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats. Pharmacol. Biochem. Behav. 2004, 78, 683-689.
172. Di Mascio, M.; Di Giovanni, G.; Di Matteo, V.; Prisco, S.; Esposito, E. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res. Bull. 1998, 46, 547-554.
173. Gaddum, J. H. Drugs antagonistic to 5-hydroxytryptamine. In Ciba foundation symposium on hypertension, Wolstenholme GH Eds.; Little Brown and Company: Boston, 1954, pp 75-77.
174. Wooley, D. W.; Shaw. E. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. USA 1954, 40, 228-231
175. Snyder, S. H. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am. J. Psychiat. 1973, 130, 61-67.
176. Altar, C. A.; Wasley, A, M.; Neale, R. F.; Stone, G. A. Typical and atypical antipsychotic occupancy of D2, and S2 receptors: an autoradiographic analysis in rat brain. Brain Res. Bull. 1986, 16, 517-525.
177. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapinc for the treatment-resistent schizophrenic. A double-blind camperison with chlorpromazine. Arch. Gen. Psychiatty 1988, 45, 789-796.
178. Schmidt, C. J.; Sorensen, S. M.; Kehne, J. H.; Carr, A. A.; Palfreymann, M. G. The role of 5-HT2A receptors in antipsychotic activitv. Life Sci. 1995, 25, 2209-2222.
179. Ashby, C. R.; Wang, R. Y.; Pharmacological actions of the atypical antipsychotic drug clozapine. A review. Synapse 1996, 24, 349-394.
180. Meltzer, H. Y.; Nash, J. F. VII. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 1991, 43, 587-604.
181. Roth, B.L.; Roland, D.; Ciaranello, D.; Meltzer, H.Y. Binding of typical and atypical antipyschotic agents to transiently expressed 5-HT1C receptors. J. Pharmacol. Exp. Ther. 1992, 260, 1361-1365.
182. Leysen, J. E.; Gommeren, W.; Van Gompel, P.; Wynants, J.; Janssen, P. F.; Laduron, P. M. Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist Mol. Pharmacol. 1985, 27, 600-611.
183. Schotte, A.; de Bruyckere, K.; Janssen, P. F.; Leysen, J. E. Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography. Brain Res. 1989, 500, 295-301.
184. Bersani, G.; Grispini, A.; Marini, S.; Pasini, A.; Valducci, M.; Ciani, N. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin. Neuropharmacol. 1990, 13, 500-506.
185. Miller, C. H.; Fleischhacker, W. W.; Ehrmann, H.; Kane, J. M. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychoparin. Bull. 1990, 26, 373-376.
186. Canton, H.; Verrièle, L.; Colpaert F.C. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. Eur. J. Pharmacol. 1990, 191, 93-96.
187. Canton, H.; Verrièle, L.; Millan, M. J. Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci. Lett. 1994, 181, 65-68.
188. Kuoppamäki, M.; Syvälahti, E.; Jetala, J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonist. Eur. J. Pharmacol. 1993, 245, 179-182.
189. Kuoppamäki, M.; Pälvimäki, E. P.; Jetala, J.; Syvälahti, E. Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 1995, 13, 139-150.
190. Schotte, A.; Janssen, P. F. M.; Megens, A. A. H.,P.; Leysen, J. E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 1993, 631, 191-202.
191. Schotte, A.; Janssen, P. F. M.; Gommeren, W.; Luyten, W. H. M. L.; Van Gompel, P.; Lesage, A. S.; De Loore, K.; Leysen, J. E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacolgy 1996, 124, 57-73.
192. Di Matteo, V.; Cacchio, M.; Di Giulio, C.; Di Giovanni, G.; Esposito, E. Biochemical evidence that the atypical antipsychotic drugs clozapine and risperidone block 5-HT2C receptors in vivo. Pharmacol. Biochem. Behav. 2002, 71, 607-613.
193. Shilliam, C. S.; Dawson, L. A. The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT(2C) receptor antagonist. Neuropsychopharmacology 2005, 30, 372-380.
194. Prinssen, E. P. M.; Koek, W.; Kleven, M. S. The effects of antipsychotics with 5-HT2C receptor affinity in behavioral assays selective for 5-HT2C receptor antagonist properties of compounds. Eur. J. Pharmacol. 2000, 388, 57-67.
195. Herrick-Davis, K.; Grinde, E.; Teitler, M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J. Pharmacol. Exp. Ther. 2000, 295, 226-232.
196. Kuroki, T.; Meltzer, H. Y.; Ichikawa, J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 1999, 288, 774-781.
197. Reavill, C.; Kettle, A.; Holland, V.; Riley, G.; Blackburn, T. P. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br. J. Pharmacol. 1999, 126, 572-574.
198. Albin, R.; Young, A. B.; Penney, J. B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12, 366-375.
199. Hagan, J. J.; Middlemiss, D. N.; Sharp, P. C,; Poste, G. H. Parkinson's disease: prospects for improved drug therapy. Trends Pharmacol. Sci. 1997, 18, 156-63.
200. Agid, Y. Levodopa: is toxicity a myth? Neurology 1998, 50, 858-863.
201. Rodriguez, M. C.; Obeso, J. A.; Olanow, C. W. Subthalamic nucleus-mediated excitoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 1998, 44, S175-S188.
202. Fox, S. H.; Brotchie, J. M. A role for 5-HT2C receptor antagonists in the treatment of Parkinson's disease? Drugs News Perspect. 1999, 12, 477-483.
203. Radja, F.; Descarrier, L.; Dewar, K. M.; Reader, T. A. Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study. Brain Res. 1993, 606, 273-285
204. Fox, S. H.; Brotchie, J. M. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov. Disord. 2000, 15, 1064-1069.
205. Fox, S. H.; Brotchie, J. M. 5-HT2C receptor antagonists enhance the behavioural response to dopamine D1 receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur. J. Pharmacol. 2000, 398, 59-64.
206. Wolf, W.A.; Bieganski, G. J.; Guillen, V.; Mignon, L. Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy. Psychopharmacology 2005, 182, 84-94.
207. Fox, S. H.; Moser, B.; Brotchie, J. M. Behavioural effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 1998, 151, 35-49.
208. Blackburn, T. P. Serotonergic agents and Parnkinson's disease. Drug Disc. Today 2004, 1, 35-41.
209. Koob, G. F. Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 1992, 13, 177-184.
210. Di Chiara, G.; Imperato, A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad Sci. USA 1988, 85, 5274-5278.
211. Spanagel, R.; Weiss, F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 1999; 22, 521-527.
212. Maurel-Remy, S.; Bervoets, K.; Millan, M. J. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur. J. Pharmacol. 1995, 280, R9-R11.
213. Kehne, J. H.; Ketteler, H. J.; McCloskey, T. C.; Sullivan, C. K.; Dudley, M. W.; Schmidt C. J. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 1996, 15, 116-124.
214. Schmidt, C. J.; Fadayel, G. M.; Sullivan, C. K.; Taylor, V. L. 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: Studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 1992, 223, 65-74.
215. Bankson, G. M.; Cunningham, K. A. Pharmacological studies of the acute effects of (+)-3,4-Methylenedioxymethamphetamine on locomotor activity: role of 5-HT1B/1D and 5-HT2 receptors. Neuropsychopharmacology 2002, 26, 40-52
216. Fletcher, P. J.; Phil, D.; Grottick, A.J.; Higgins, G. A. Differential effects of the 5-HT2A receptor antagonist M100,907 and the 5-HT2C receptor antagonist SB242,084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 2002, 27, 576-586.
217. Porras, G.; Di Matteo, V.; Fracasso, C.; Lucas, G.; De Deurwaerdère, P.; Caccia, S.; Esposito, E.; Spampinato, U. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 2002, 26, 311-324.
218. O'Neill, M. F.; Heron-Maxwell, C. L.; Shaw, G. 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. Pharmacol. Biochem. Behav. 1999, 63, 237-243.
219. McMahon, L. R.; Cunningham, K. A. Antagonism of 5-Hydroxytryptamine2A receptors attenuates the behavioral effects of cocaine in rats. J. Pharmacol. Exp. Ther. 2001, 297, 357-363.
220. McCreary, A. C.; Cunningham, K. A. Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine. Neuropsychopharmacoloy 1999, 20, 556-564.
221. Grottick; A. J.; Fletcher, P. J.; Higgins, G. A. Studies to investigate the role of 5-HT2C receptors on cocaine- and food-maintained behavior. J. Pharmacol. Exp. Ther. 2000, 295, 1183-1191.
222. Tomkins, D. M.; Joharchi, N.; Tampakeras, M.; Martin, J. R.; Wichmann, J.; Higgins, G. A. An investigation of the role of 5-HT2C receptors in modifying ethanol self-administration behaviour. Pharmacol. Biochem. Behav. 2002, 71, 735-744.
223. Grottick, A. J.; Corrigall, W. A,; Higgins, G. A. Activation of 5-HT2C receptors reduces the locomotor and rewarding effects of nicotine. Psychopharmacology 2001, 157, 292-298.
224. Pierucci, M.: Di Matteo, V.; Esposito, E. Stimulation of serotonin2C receptors blocks the hyperactivation of midbraindopamine neurons induced by nicotine administration. J Pharmacol. Exp. Ther. 2004, 309, 109-118.
225. Di Matteo, V.; Pierucci, M.; Esposito, E. Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration. J. Neurochem. 2004, 89, 418-429.